Literature DB >> 17629534

Detection of hepatitis G virus envelope protein E2 antibody in blood donors.

Amitis Ramezani1, Latif Gachkar, Ali Eslamifar, Manoochehr Khoshbaten, Somayeh Jalilvand, Ladan Adibi, Vahid Salimi, Rasool Hamkar.   

Abstract

OBJECTIVES: The frequency of hepatitis G virus exposure in blood donors varies between 2.5% in Japan to 24.2% in Poland. Therefore there is a geographic difference in distribution of hepatitis G virus (HGV) in the world. We aimed to determine the frequency of HGV exposure in Iranian blood donors.
METHODS: Blood samples from 478 Iranian volunteer blood donors were tested. Positive anti-E2 samples were tested for HGV RNA by reverse transcriptase polymerase chain reaction (RT PCR) using primers derived from the NS5A region of the viral genome.
RESULTS: Of the 478 donors enrolled in our study, five (1%) were positive for anti-E2. Only one donor out of a total of three HBsAg-positive donors was co-infected with HGV, but we did not find HGV and HCV co-infection in our subjects. HGV RNA was not observed in the five anti-E2-positive subjects. We did not find HGV viremia and antibody at the same time.
CONCLUSION: A low frequency of HGV exposure in blood donors was found in this study. We did not observe co-infection of HGV with HCV in our subjects, supporting the theory that although the parenteral route is the most effective means of transmission, other routes such as sexual contact and intra-familial contact may also play a role in HGV transmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629534     DOI: 10.1016/j.ijid.2007.04.010

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

Review 1.  GBV-C: state of the art and future prospects.

Authors:  Maria Teresa Maidana Giret; Esper Georges Kallas
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection.

Authors:  B Boodram; R C Hershow; D Klinzman; J T Stapleton
Journal:  J Viral Hepat       Date:  2011-04       Impact factor: 3.728

3.  Emerging infectious threats to the blood supply: seroepidemiological studies in iran - a review.

Authors:  Gharib Karimi; Ahmad Gharehbaghian; Mohammad Fallah Tafti; Vida Vafaiyan
Journal:  Transfus Med Hemother       Date:  2013-05-17       Impact factor: 3.747

4.  Prevalence, incidence density, and genotype distribution of GB virus C infection in a cohort of recently HIV-1-infected subjects in Sao Paulo, Brazil.

Authors:  Maria Teresa M Giret; João Luiz Miraglia; Maria Cecília Araripe Sucupira; Anna Nishiya; José Eduardo Levi; Ricardo S Diaz; Ester C Sabino; Esper G Kallas
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

5.  Frequency and genotypic distribution of GB virus C (GBV-C) among Colombian population with Hepatitis B (HBV) or Hepatitis C (HCV) infection.

Authors:  Mónica V Alvarado-Mora; Livia Botelho; Anna Nishiya; Raymundo A Neto; Michele S Gomes-Gouvêa; Maria F Gutierrez; Flair J Carrilho; João Rr Pinho
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

6.  Association between Hepatitis G and Unknown Chronic Hepatitis.

Authors:  Saeed Soleiman-Meigooni; Ali Asgari; Seyyed Javad Hoseini-Shokouh; Jalil Rajabi; Mohammad Hassan Kazemi-Galougahi; Mohammad Moshtaghi
Journal:  Electron Physician       Date:  2015-03-01

7.  GB virus C Viremia and Anti-E2 Antibody Response Among Hemodialysis Patients in Gorgan, Iran.

Authors:  Mishar Kelishadi; Mohammad Mojerloo; Abdolvahab Moradi; Masoud Bazouri; Pezhman Hashemi; Sobhan Samadi; Atefeh Saeedi; Alijan Tabarraei
Journal:  Jundishapur J Microbiol       Date:  2014-11-01       Impact factor: 0.747

Review 8.  Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.

Authors:  Mehdi Samadi; Vahid Salimi; Mohammad Reza Haghshenas; Seyed Mohammad Miri; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Virol J       Date:  2022-03-09       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.